Skip to Content Skip to Search

North Macedonia

Please select...

Disclosure of payments made to HCPs in North Macedonia

As part of our goal to be one of the most innovative, best performing and trusted healthcare companies in the world, we seek to meet society’s evolving expectations, bring greater transparency to an already well-regulated industry, and strengthen our relationships with Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs) future collaboration.

Cooperation between pharmaceutical companies, regulators, HCPs, HCOs, and patients, is essential for the sustainable improvement of healthcare. These relationships have helped deliver numerous innovative new medicines and changed the way many diseases impact on our lives. HCPs have always been, and will always be, valuable partners for GSK. As experts in their field, they provide us with first hand scientific and medical knowledge and unique insights into patient care. This partnership is fundamental to the progression of medical science, helping to meet patient and public health needs.

Under the EFPIA Disclosure Code, from 2016 EFPIA member companies, which Farmabrend Nova is a part of since 2019, pledged to disclose the transfers of value they make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes, for example, sponsorship for travel and registration fees to attend medical congresses, HCP consultancy fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.

Transfer of value disclosure information is published annually (covering the previous year) on a public platform; either the company’s own website or, in some countries, a central platform combining data from different companies.

Our disclosures for North Macedonia

There is no transfer of values from GSK North Macedonia for the reporting year 2021 to be disclosed.


For media enquiries, please contact:

Back to top